A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

@article{Yazici2017ANW,
  title={A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.},
  author={Yusuf Yazici and Timothy E. McAlindon and Roy Fleischmann and Alan Gibofsky and Nancy E. Lane and Alan J. Kivitz and Nebojsa Skrepnik and E D Armas and Christopher J. Swearingen and ario DiFrancesco and J R S Tambiah and Jay Hood and Marc C. Hochberg},
  journal={Osteoarthritis and cartilage},
  year={2017},
  volume={25 10},
  pages={
          1598-1606
        }
}
OBJECTIVE To assess the safety, pharmacokinetics, and exploratory efficacy of SM04690, a novel Wnt pathway inhibitor, as a potential disease modifying treatment for knee osteoarthritis (OA). DESIGN Subjects with Kellgren-Lawrence grade 2-3 knee OA were randomized in successive dose-escalation cohorts to receive a knee intra-articular (IA) injection with 0… CONTINUE READING